179 related articles for article (PubMed ID: 36968212)
1. Chronic hypoxia is associated with transcriptomic reprogramming and increased genomic instability in cancer cells.
Abou Khouzam R; Sharda M; Rao SP; Kyerewah-Kersi SM; Zeinelabdin NA; Mahmood AS; Nawafleh H; Khan MS; Venkatesh GH; Chouaib S
Front Cell Dev Biol; 2023; 11():1095419. PubMed ID: 36968212
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia increases mutational load of breast cancer cells through frameshift mutations.
Hassan Venkatesh G; Bravo P; Shaaban Moustafa Elsayed W; Amirtharaj F; Wojtas B; Abou Khouzam R; Hussein Nawafleh H; Mallya S; Satyamoorthy K; Dessen P; Rosselli F; Thiery J; Chouaib S
Oncoimmunology; 2020; 9(1):1750750. PubMed ID: 32363122
[TBL] [Abstract][Full Text] [Related]
3. Interaction Among Noncoding RNAs, DNA Damage Reactions, and Genomic Instability in the Hypoxic Tumor: Is it Therapeutically Exploitable Practice?
Ray SK; Mukherjee S
Curr Mol Med; 2023; 23(3):200-215. PubMed ID: 35048804
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment.
Scanlon SE; Glazer PM
DNA Repair (Amst); 2015 Aug; 32():180-189. PubMed ID: 25956861
[TBL] [Abstract][Full Text] [Related]
5. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Chalmers ZR; Connelly CF; Fabrizio D; Gay L; Ali SM; Ennis R; Schrock A; Campbell B; Shlien A; Chmielecki J; Huang F; He Y; Sun J; Tabori U; Kennedy M; Lieber DS; Roels S; White J; Otto GA; Ross JS; Garraway L; Miller VA; Stephens PJ; Frampton GM
Genome Med; 2017 Apr; 9(1):34. PubMed ID: 28420421
[TBL] [Abstract][Full Text] [Related]
6. An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.
Cao J; Chen L; Li H; Chen H; Yao J; Mu S; Liu W; Zhang P; Cheng Y; Liu B; Hu Z; Chen D; Kang H; Hu J; Wang A; Wang W; Yao M; Chrin G; Wang X; Zhao W; Li L; Xu L; Guo W; Jia J; Chen J; Wang K; Li G; Shi W
Oncologist; 2019 Dec; 24(12):e1294-e1302. PubMed ID: 31409745
[TBL] [Abstract][Full Text] [Related]
7. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
[TBL] [Abstract][Full Text] [Related]
8. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
9. Breast tumor copy number aberration phenotypes and genomic instability.
Fridlyand J; Snijders AM; Ylstra B; Li H; Olshen A; Segraves R; Dairkee S; Tokuyasu T; Ljung BM; Jain AN; McLennan J; Ziegler J; Chin K; Devries S; Feiler H; Gray JW; Waldman F; Pinkel D; Albertson DG
BMC Cancer; 2006 Apr; 6():96. PubMed ID: 16620391
[TBL] [Abstract][Full Text] [Related]
10. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
11. Genomic heterogeneity and copy number variant burden are associated with poor recurrence-free survival and 11q loss in human papillomavirus-positive squamous cell carcinoma of the oropharynx.
Schrank TP; Lenze N; Landess LP; Hoyle A; Parker J; Lal A; Sheth S; Chera BS; Patel SN; Hackman TG; Major MB; Issaeva N; Yarbrough WG
Cancer; 2021 Aug; 127(15):2788-2800. PubMed ID: 33819343
[TBL] [Abstract][Full Text] [Related]
12. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
13. Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy.
Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Serizawa M; Maruyama K; Naruoka A; Akiyama Y; Urakami K; Kusuhara M; Mochizuki T; Yamaguchi K
Cancer Sci; 2019 Aug; 110(8):2620-2628. PubMed ID: 31152682
[TBL] [Abstract][Full Text] [Related]
14. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
[No Abstract] [Full Text] [Related]
15. Downregulation of both mismatch repair and non-homologous end-joining pathways in hypoxic brain tumour cell lines.
Cowman S; Pizer B; Sée V
PeerJ; 2021; 9():e11275. PubMed ID: 33986995
[TBL] [Abstract][Full Text] [Related]
16. Tumor Hypoxia Drives Genomic Instability.
Tang M; Bolderson E; O'Byrne KJ; Richard DJ
Front Cell Dev Biol; 2021; 9():626229. PubMed ID: 33796526
[TBL] [Abstract][Full Text] [Related]
17. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
Dai J; Jiang M; He K; Wang H; Chen P; Guo H; Zhao W; Lu H; He Y; Zhou C
Front Oncol; 2021; 11():708294. PubMed ID: 34604048
[TBL] [Abstract][Full Text] [Related]
18. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
19. Alteration in glycolytic/cholesterogenic gene expression is associated with bladder cancer prognosis and immune cell infiltration.
Zhang Y; Zhu B; Cai Y; Zhu S; Zhao H; Ying X; Jiang C; Zeng J
BMC Cancer; 2022 Jan; 22(1):2. PubMed ID: 34980012
[TBL] [Abstract][Full Text] [Related]
20. Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients.
Hatakeyama K; Nagashima T; Ohshima K; Ohnami S; Ohnami S; Shimoda Y; Naruoka A; Maruyama K; Iizuka A; Ashizawa T; Mochizuki T; Urakami K; Akiyama Y; Yamaguchi K
Cancer Sci; 2020 Oct; 111(10):3893-3901. PubMed ID: 32662546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
